

## LITERATURA

1. Berg K. A New Serum Type System in Man – The LP System. *Acta Pathol Microbiol Scand.* 1963;59:369-82.
2. Pyörälä K, De Backer G, Graham I, et al. Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. *Eur Heart J.* 1994;15:1300-31.
3. Nordestgaard BG, Chapman MJ, Ray K, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. *Eur Heart J.* 2010;31:2844-53.
4. Kronenberg F, Mora S, Stroes ESG, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. *Eur Heart J.* 2022;43:3925-46.
5. Vrablík M, Cífková R, Freiburger T, et al. Stanovisko ČSAT ke Konsenzu Evropské společnosti pro aterosklerózu: Lipoprotein(a) při aterosklerotických kardiovaskulárních onemocněních a aortální stenóze. *AtheroRev.* 2023;8:66-76.
6. Bláha V. Lipoprotein(a) – the cardiovascular risk factor: significance and therapeutic possibilities. *Vnitřní lékařství.* 2019;64:1160-8.
7. Erqou S, Thompson A, Di Angelantonio E, et al. Apolipoprotein(a) isoforms and the risk of vascular disease: systematic review of 40 studies involving 58,000 participants. *Journal of the American College of Cardiology.* 2010;55:2160-7.
8. Mehta A, Jain V, Saeed A, et al. Lipoprotein(a) and ethnicities. *Atherosclerosis.* 2022;349:42-52.
9. Sandholzer C, Saha N, Kark JD, et al. Apo(a) isoforms predict risk for coronary heart disease. A study in six populations. *Arteriosclerosis and thrombosis: a journal of vascular biology / American Heart Association.* 1992;12:1214-26.
10. Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. *Jama.* 2009;301:2331-9.
11. Willeit P, Ridker PM, Nestel PJ, et al. Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials. *Lancet.* 2018;392:1311-20.
12. Lamina C. Mendelian Randomization: Principles and its usage in Lp(a) research. *Atherosclerosis.* 2022;349:36-41.
13. Nordestgaard BG, Langsted A. Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology. *Journal of lipid research.* 2016;57:1953-75.
14. Kamstrup PR, Nordestgaard BG. Elevated Lipoprotein(a) Levels, LPA Risk Genotypes, and Increased Risk of Heart Failure in the General Population. *JACC Heart Fail.* 2016;4:78-87.
15. Langsted A, Nordestgaard BG, Kamstrup PR. Elevated Lipoprotein(a) and Risk of Ischemic Stroke. *Journal of the American College of Cardiology.* 2019;74:54-66.
16. Arnold M, Schweizer J, Nakas CT, et al. Lipoprotein(a) is associated with large artery atherosclerosis stroke aetiology and stroke recurrence among patients below the age of 60 years: results from the BIOSIGNAL study. *Eur Heart J.* 2021;42:2186-96.
17. Pan Y, Li H, Wang Y, Meng X, Wang Y. Causal Effect of Lp(a) (Lipoprotein(a)) Level on Ischemic Stroke and Alzheimer Disease: A Mendelian Randomization Study. *Stroke; a journal of cerebral circulation.* 2019;50:3532-9.
18. Arsenault BJ, Boekholdt SM, Dubé MP, et al. Lipoprotein(a) levels, genotype, and incident aortic valve stenosis: a prospective Mendelian randomization study and replication in a case-control cohort. *Circ Cardiovasc Genet.* 2014;7:304-10.
19. Kamstrup PR, Tybjaerg-Hansen A, Nordestgaard BG. Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population. *Journal of the American College of Cardiology.* 2014;63:470-7.
20. Gudbjartsson DF, Thorgeirsson G, Sulem P, Helgadóttir A, et al. Lipoprotein(a) Concentration and Risks of Cardiovascular Disease and Diabetes. *Journal of the American College of Cardiology.* 2019;74:2982-94.
21. Parish S, Hopewell JC, Hill MR, et al. Impact of Apolipoprotein(a) Isoform Size on Lipoprotein(a) Lowering in the HPS2-THRIVE Study. *Circ Genom Precis Med.* 2018;11:e001696.
22. Waldmann E, Parhofer KG. Lipoprotein apheresis to treat elevated lipoprotein (a). *Journal of lipid research.* 2016;57:1751-7.
23. O'Donoghue ML, Fazio S, Giugliano RP, et al. Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk. *Circulation.* 2019;139:1483-92.
24. Szarek M, Bittner VA, Aylward P, et al. Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial. *Eur Heart J.* 2020;41:4245-55.
25. O'Donoghue ML, Rosenson RS, Gencer B, et al. Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease. *The New England journal of medicine.* 2022;387:1855-64.
26. Tsimikas S, Karwadowska-Prokopczuk E, Gouni-Berthold I, et al. Lipoprotein(a) Reduction in Persons with Cardiovascular Disease. *The New England journal of medicine.* 2020;382:244-55.
27. Nicholls SJ, Nissen SE, Fleming C, et al. Muvalaplin, an Oral Small Molecule Inhibitor of Lipoprotein(a) Formation: A Randomized Clinical Trial. *Jama.* 2023;330:1042-53.
28. Nissen SE, Linnebjerg H, Shen X, et al. Lepodisiran, an Extended-Duration Short Interfering RNA Targeting Lipoprotein(a): A Randomized Dose-Ascending Clinical Trial. *Jama.* 2023;330:2075-83.
29. Lee RG, Mazzola AM, Braun MC, Platt C, et al. Efficacy and Safety of an Investigational Single-Course CRISPR Base-Editing Therapy Targeting PCSK9 in Nonhuman Primate and Mouse Models. *Circulation.* 2023;147:242-53.
30. Doerfler AM, Park SH, Assini JM, et al. LPA disruption with AAV-CRISPR potentially lowers plasma apo(a) in transgenic mouse model: A proof-of-concept study. *Mol Ther Methods Clin Dev.* 2022;27:337-51.
31. Scharnagl H, Stojakovic T, Dieplinger B, et al. Comparison of lipoprotein (a) serum concentrations measured by six commercially available immunoassays. *Atherosclerosis.* 2019;289:206-13.
32. van Buuren F, Horstkotte D, Knabbe C, Hinse D, Mellwig KP. Incidence of elevated lipoprotein (a) levels in a large cohort of patients with cardiovascular disease. *Clin Res Cardiol Suppl.* 2017;12:55-9.

**FACEBOOK**<https://www.facebook.com/SolenMedicalEducation/>

@SolenMedicalEducation

**X**<https://twitter.com/MedicalSolen>

@MedicalSolen

**LINKEDIN**<https://www.linkedin.com/company/solen-medical-education/>

#solenmedicaleducation

» ODEMČENÉ **AKTUÁLNÍ ČLÁNKY**» **PŘEHLED** O VZDĚLÁVACÍCH AKCÍCH» UPOZORNĚNÍ NA **ZVÝHODNĚNÉ CENY**» **SOUTĚŽE** O VSTUPENKY NA KONGRESY» INFORMACE O **ON-LINE** KURZECH» NOVINKY V **E-SHOPU**

... a mnoho dalšího

... **nenechte si ujít aktuální informace**  
o možnostech medicínského vzdělávání